September 2020 in “Scientific periodicals of Ukraine” "Flosin – Prostamol Uno" effectively manages BPH symptoms with fewer side effects.
March 2005 in “European Urology Supplements” April 2026 in “Therapeutic Advances in Drug Safety” Finasteride is high-risk for cognitive disorders, while Carbidopa/Levodopa, Topiramate, and Clonazepam are moderate-risk.
November 2008 in “Cancer Prevention Research” Chemoprevention can significantly lower cancer risks and needs more research and collaboration.
January 2026 in “Elsevier eBooks” September 2004 in “Inpharma Weekly” January 2012 in “Chinese Clinical Oncology” Disodium folinate can safely and effectively replace calcium folinate in colorectal cancer treatment.
11 citations
,
January 2020 in “Engineered science”
June 2019 in “Reactions Weekly”
109 citations
,
March 2011 in “Journal of controlled release” New micelle solutions greatly improve skin delivery of certain antifungal drugs.
186 citations
,
December 2011 in “Molecules” Three specific 4-azasteroid-2-oximes showed strong enzyme inhibition, but less than finasteride.
January 2011 in “Reactions Weekly” May 2024 in “Reactions weekly”
April 2018 in “Journal of Investigative Dermatology” BLZ-100 is safe for use in skin cancer surgery and may help identify cancerous tissue.
August 2002 in “Inpharma Weekly” October 2024 in “bioRxiv (Cold Spring Harbor Laboratory)” Rodent models of PCOS show some similar and some different lipid changes compared to humans.
6 citations
,
August 2013 in “한국응용생명화학회지” Certain natural compounds can block an enzyme linked to prostate enlargement and hair loss, showing potential for new treatments.
February 2006 in “Inpharma Weekly”
3 citations
,
January 2018 in “Journal of South Asian Federation of Obstetrics and Gynaecology” Letrozole is better for single follicle development and endometrial thickness in PCOS, with no significant difference in pregnancy rates compared to clomiphene.
November 2005 in “The Journal of Urology” 16 citations
,
March 1986 in “Biochemical Pharmacology” May 2022 in “Reactions Weekly” IVL-DrugFluidic® can mass-produce high-quality, long-acting injectable drug microspheres, improving patient compliance and reducing side effects.
3 citations
,
October 1994 in “Journal of Labelled Compounds and Radiopharmaceuticals” Scientists made a carbon-14 labeled version of a drug with a 48% yield and over 99% purity.